Home > Publications >AT-527, a Double Prodrug of a Guanosine Nucleotide Analog, Is a Potent Inhibitor of SARS-CoV-2 In Vitro and a Promising Oral Antiviral for Treatment of COVID-19 >

<<Previous Next>>

Post Date:Jul-29-21

AT-527, a Double Prodrug of a Guanosine Nucleotide Analog, Is a Potent Inhibitor of SARS-CoV-2 In Vitro and a Promising Oral Antiviral for Treatment of COVID-19

AcceGenAuthor: AcceGen R&D Team

Date Published: 29-Jul-21

AT-527, a Double Prodrug of a Guanosine Nucleotide Analog, Is a Potent Inhibitor of SARS-CoV-2 In Vitro and a Promising Oral Antiviral for Treatment of COVID-19

  • Authors: Steven S. Good, Jonna Westover, Kie Hoon Jung, Xiao-Jian Zhou, Adel Moussa, Paolo La Colla, Gabriella Collu, Bruno Canard, and Jean-Pierre Sommadossi
  • Journal: Jornal of Clinical Microbiology
  • DOI: 10.1128/AAC.02479-20
  • Cited AcceGen Product/Service:

<<Previous Next>>

AcceGen Scroll Top Button
Copy link